Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695628 · ClinicalTrials.gov registry record · Phase 2
[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02695628: Completed Phase 2 study, sponsored by Stanford University.
NCT02695628 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02695628, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This clinical trial studies how well 18F-fluoromisonidazole (\[18F\]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor. \[18F\]FMISO is a type of radioimaging agent that binds to large molecules in tumor cells that have a low level of oxygen, and the radiation given off by \[18F\]FMISO is picked up by a PET scan and this may help researchers learn whether changes occur in the tumors after treatment, which can help decide how well the treatment worked earlier than is currently possible
Interventions
- PROCEDURE Arterial Embolization
- DIAGNOSTIC_TEST Computed Tomography
- DRUG 18F-Fluoromisonidazole
- DIAGNOSTIC_TEST Positron Emission Tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02695628
The ClinicalTrials.gov registry entry for NCT02695628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Arterial Embolization is the first listed.
NCT02695628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02695628 about?
NCT02695628 is a clinical study titled "[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer". This clinical trial studies how well 18F-fluoromisonidazole (\[18F\]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells...
What is the current status of trial NCT02695628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2016-09-13. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT02695628?
The interventions under investigation include: Arterial Embolization (PROCEDURE), Computed Tomography (DIAGNOSTIC_TEST), 18F-Fluoromisonidazole (DRUG), Positron Emission Tomography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02695628?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.